Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03951012 · ClinicalTrials.gov registry record
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
A clinical trial, sponsored by Muhammad Furqan.
- Terminated
- Registry status
- 29
- Enrollment target
NCT03951012 is a clinical trial that was terminated before completion, run by Muhammad Furqan. The registered enrollment target is 29 participants.
The verdict
NCT03951012 was terminated before completion, sponsored by Muhammad Furqan.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
Peripheral blood contains enormous quantity of biological information that can improve our patient care. Investigators plan to use proteomics from serum to study its value in predicting the therapeutic response and toxicities of immunotherapy in non-small cell lung cancer (NSCLC).
Interventions
- PROCEDURE Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2023-09-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03951012
The ClinicalTrials.gov registry entry for NCT03951012 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Muhammad Furqan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT03951012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03951012 about?
NCT03951012 is a clinical study titled "Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy". Peripheral blood contains enormous quantity of biological information that can improve our patient care. Investigators plan to use proteomics from serum to study its value in predicting the therapeutic response and toxicities of immunotherapy in non-small cell lung cancer (NSCLC).
What is the current status of trial NCT03951012?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2019-04-15. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT03951012?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT03951012?
This trial is sponsored by Muhammad Furqan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.